Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree

Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree

BACKGROUND: The hepatitis C virus (HCV) prevalence rate among injection drug users (IDUs) in North America is 55.2%, with 1.41 million individuals estimated to be HCV-antibody positive. Studies have shown the effectiveness of syringe service programs (SSPs) alone, medications for opioid use disorder...

Full description

Bibliographic Details
Main Authors: Carroll, N.V (Author), Holdford, D.A (Author), Ijioma, S.C (Author), Pontinha, V.M (Author)
Format: Article
Language:English
Published: Academy of Managed Care Pharmacy (AMCP) 2021
Subjects:
adverse event
Analgesics, Opioid
antiviral therapy
antivirus agent
Article
complication
cost benefit analysis
cost control
cost effectiveness analysis
Cost-Benefit Analysis
decision tree
Decision Trees
drug use
Drug Users
economics
harm reduction
Harm Reduction
health care cost
health program
health service
hepatitis C
Hepatitis C
high risk behavior
human
Humans
injection drug user
major clinical study
medical decision making
narcotic analgesic agent
needle sharing
Needle Sharing
Needle-Exchange Programs
opiate
opiate addiction
opiate substitution treatment
Opiate Substitution Treatment
Opioid-Related Disorders
organization and management
prevalence
Prevalence
preventive health service
psychology
quality adjusted life year
Quality-Adjusted Life Years
risk behavior
Risk-Taking
sensitivity analysis
substance abuse
Substance Abuse, Intravenous
United States
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items